Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 5G23D / D947X | IM / RL |
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Kinrix vaccine administered to infant; Wrong dose Vaccine was given twice; Expired vaccine used; Kinrix vaccine administered to infant; This non-serious case was reported by a other health professional via patient support programs and described the occurrence of inappropriate age at vaccine administration in a 12-week-old female patient who received DTPa-IPV (Kinrix) (batch number 5G23D / D947X, expiry date 25-JAN-2025) for prophylaxis. Co-suspect products included DTPa-IPV (Kinrix) for prophylaxis. On 28-JAN-2025, the patient received Kinrix (intramuscular, right thigh). On 27-NOV-2024, the patient received Kinrix. On 27-NOV-2024, not applicable after receiving Kinrix and an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Kinrix vaccine administered to infant). On 28-JAN-2025, the patient experienced inappropriate age at vaccine administration (Verbatim: Kinrix vaccine administered to infant), extra dose administered (Verbatim: Wrong dose Vaccine was given twice) and expired vaccine used (Verbatim: Expired vaccine used). The outcome of the inappropriate age at vaccine administration, inappropriate age at vaccine administration, extra dose administered and expired vaccine used were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-FEB-2025 This case was reported by a medical assistant via patient support programs. The patient received wrong dose. The patient received expired dose of Kinrix, which led to expired vaccine used. No other products were reported.